Questions? Feedback? powered by Olark live chat software
All Site

screeningBetween 1990 and 2006 one third of all safety-related drug withdrawals were due to cardiotoxicity, and cardiac liability continues to be a major hurdle in drug development. There are ongoing efforts to develop higher throughput and more predictive assays that can be used earlier in the drug discovery/development pipeline to minimize both cost and risk. In Vitro Technologies provides a complete drug discovery and compound screening platform using the label-free, real-time cell analysis technologies from Agilent and ACEA Biosciences.

  • xCELLigence SP & MP RTCA
  • xCELLigence Cardio & CardioECR RTCA
  • TocriScreen compound libraries
  • Seahorse XF analyzer

Learn more about our range by clicking on the buttons below

t cell meta
t high throughput
t compound libraries
t realtime
t luminex

Our Cardiotoxicity & Drug Discovery Brands

/brands/agilent-technologies-seahorse-bioscience/

/brands/acea-biosciences

tocris

/brands/corning

randd logo